Built-in Blocker: Drug and antidote in the same molecule

In cases of serious side effects or overdoses of medications, it can be vital to have a fast-acting antidote on hand. This is especially true of drugs that inhibit blood clotting, which are used to prevent and treat thromboses and embolisms, to treat heart attacks, and, in higher doses, in dialysis and in heart surgeries involving a heart-lung machine. Overdoses can lead to life-threatening hemorrhages.

Unfractionated heparin is so far the only blood-clotting inhibitor for which a specific antidote exists. This classic thus continues to be the fallback agent for patients with a high risk of bleeding and in applications requiring rapid reversal of the anticoagulating effect, even though a number of newly developed blood-clotting inhibitors would be more advantageous with regard to their other characteristics.

A research team led by Alexander Heckel, Günter Mayer, and Bernd Pötzsch in Bonn, Germany, has now developed an anticoagulant that brings along its own antidote. Irradiation with UV light activates the part of the molecule that acts as the antidote, which almost immediately halts the blood-clotting inhibition.

This new substance is based on an aptamer that binds to thrombin, a key protein in blood clotting, and blocks it. Aptamers are short, single strands of nucleic acid (DNA) that can bind to another molecule—thrombin in this case—with strength and specificity similar to those of an antibody. In doing this, the aptamer folds into a three-dimensional structure that is perfectly tailored to the structure of the target molecule. The researchers bound another short DNA strand to the thrombin-binding aptamers. This fragment can act as antidote as soon as its “starter” is activated. As long as the antidote hasn’t been activated, the new drug is a highly effective anticoagulant.

If the aptamer’s blood-clotting inhibition needs to be switched off, the drug is irradiated with UV light to activate the starter. The short antidote DNA strand is complementary (the counterpart) to a segment of the thrombin-binding aptamer strand—except for a special, slightly altered nucleotide that acts like an error in the sequence. DNA fragments that are complementary to each other have the tendency to stick together to form a double strand; however, this is initially inhibited by the altered nucleotide.

UV light causes a part of this altered nucleotide to split off, thus making it a normal nucleotide. The sequence error is removed and thus the counterpart can bind tightly to the aptamer strand, forcing the drug into a hairpin-like form. The previous three-dimensional structure of the aptamer is disrupted—and so is its bond to thrombin as well as its anticoagulating effect.

Citation: Alexander Heckel, et al., An Anticoagulant with Light-Triggered Antidote Activity, Angewandte Chemie International Edition 2006, 45, No. 40, 6748–6750, doi: 10.1002/anie.200602346

Source: Angewandte Chemie

Related stories:

Should doctors be 'selling' drugs for the pharmaceutical industry?
Feature: Key opinion leaders -- independent experts or drug representatives in disguise?
Are senior doctors who help drug companies sell their drugs independent experts or just drug representatives in disguise, asks Ray Moynihan from the University of Newcastle in Australia, in this week's BMJ.
Scientists determine drug target for the most potent botulinum neurotoxin
Botulinum neurotoxin – responsible for the deadly food poisoning disease botulism and for the beneficial effects of smoothing out facial wrinkles – can also be used as a dreaded biological weapon. When ingested or inhaled, less than a billionth of an ounce can cause muscle paralysis and eventual death. Although experimental vaccines administered prior to exposure can inhibit the destructive action of this neurotoxin – the most deadly protein known to humans – no effective pharmacological treatment exists.
Novel living system recreates predator-prey interaction
The hunter-versus-hunted phenomenon exemplified by a pack of lionesses chasing down a lonely gazelle has been recreated in a Petri dish with lowly bacteria.
Is a cup of tea really the answer to everything -- even anthrax?
A cup of black tea could be the next line of defence in the threat of bio-terrorism according to new international research.
Tooling up for tomorrow's clever cars
Cars are becoming more complex, with a range of advanced features we could hardly have imagined a few years ago made possible by sophisticated software-driven electronics. The downside is, with more to go wrong, more is going wrong, but European researchers have developed an antidote: a new computer language.
An 'attractive' man-machine interface
Researchers at Children’s Hospital Boston have developed a new “nanobiotechnology” that enables magnetic control of events at the cellular level. They describe the technology, which could lead to finely-tuned but noninvasive treatments for disease, in the January issue of Nature Nanotechnology (published online January 3).
Researchers discover fast-acting cyanide antidote
University of Minnesota Center for Drug Design and Minneapolis VA Medical Center researchers have discovered a new fast-acting antidote to cyanide poisoning. The antidote has potential to save lives of those who are exposed to the chemical – namely firefighters, industrial workers, and victims of terrorist attacks.
Go ahead, have pie (or gravy) during holidays, expert says
A Purdue University expert says people who try to deprive themselves of their favorite foods during the holiday season to avoid weight gain are setting themselves up for failure.

News discussion:

General Science news